PPT-DTG-Based Regimens Are Active in INI-Naive Patients With a

Jim Demarest 1 Mark Underwood 2 Marty St Clair 2 David Dorey 3 Steve Almond 3 Robert Cuffe 4 Dannae Brown 5 Garrett Nichols 6 1 ViiV Healthcare Global RampD Research Triangle Park NC USA . Danielle Goodrich, MSIV. University of Maryland School of Medicine . Overview. Colorectal Cancer. Bowel Preparation Regimens. Survey. 2. Colorectal Cancer . Third most common cancer. Second leading cause of cancer-related deaths. KGMU. Top five states in India which have highest number of leprosy cases. State 2009-10 2010-11 2011-12 2012-13. Uttar Pradesh 27,473 25,509 24,627 24,222. KGMU. Top five states in India which have highest number of leprosy cases. State 2009-10 2010-11 2011-12 2012-13. Uttar Pradesh 27,473 25,509 24,627 24,222. Data . from other . cohorts and . regions to guide . decisions around the use of DTG . Meg Doherty MD MPH PhD. 24 July 2018. WHO HQ. New . findings informed DTG safety . profile . among . women of child bearing potential . Dolutegravir monotherapy vs. dolutegravir/ abacavir / lamivudine for HIV-1-infected virologically suppressed patients: results from the randomized non- inferiority MONCAY trial L. Hocqueloux Nta kuaa na kee saa nruu kada nruu vita Da nroo ni mee saa maa nree dii kada ni mee ni kuko vaa ni nta kuaa ma ku xii mee nruu een een nruu daba kaa ora saa diuka na nakani ini nruu kuu kiani kuu taan introduction . of . DTG. Nandita Sugandhi. ICAP at Columbia University. No conflicts of interest to declare. Overview. Introducing . DTG in guidelines now. Programmatic Context. Eligible patient populations. Anastasiya Nestsiarovich, MD, PhD. Postdoctoral Fellow. University of New . Mexico Health Sciences Center. Department of Internal . Medicine. Center . for Global . Health. September 16, 2019. Research team:. Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society.